MREO Mereo BioPharma Group plc
Healthcare$0.33+19.91%ClosedMarket Cap: $53.3M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
1.31
P/S
88.84
EV/EBITDA
-0.21
DCF Value
$0.26
FCF Yield
-60.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
12.5%
Operating Margin
-7531.1%
Net Margin
-7139.7%
ROE
-81.3%
ROA
-87.9%
ROIC
-109.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $0.00 | -Infinity% | $-8.8M | $-6.7M | $— | — |
| Q4 null | $0.00 | NaN% | $-8.4M | $-7.4M | $— | — |
| FY null | $500.0K | 73.4% | $-38.3M | $-41.9M | $— | — |
| Q3 null | $0.00 | -Infinity% | $-10.0M | $-7.0M | $— | — |
| Q2 null | $500.0K | 73.6% | $-10.5M | $-14.6M | $— | — |
| Q1 null | $0.00 | NaN% | $-11.2M | $-12.9M | $— | — |
| Q4 null | $0.00 | -Infinity% | $-15.1M | $-7.0M | $— | — |
| FY null | $0.00 | NaN% | $-47.4M | $-43.3M | $— | — |
| Q3 null | $0.00 | NaN% | $-9.4M | $-15.0M | $— | — |
| Q2 null | $0.00 | NaN% | $-12.8M | $-12.3M | $— | — |
| Q1 null | $0.00 | NaN% | $-9.9M | $-9.0M | $— | — |
| Q4 2023 | $1.0M | 127.3% | $-7.1M | $-9.1M | $-278.56 | — |